Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORCE rituximab in refractory inflammatory myopathies and refractory generalized myasthenia gravis
2006-005900-15Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in Autoimmune Myopathies and myasthenia gravis (MG) (2 cohorts), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Muscle testing at month 12. Started May 2007; status: completed.
02
Drugs
rituximab
03
Conditions
Autoimmune Myopathiesmyasthenia gravis (MG)
Beyond the preview
Go deeper on 2006-005900-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005900-15.